PMC:7212965 / 36749-37623 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T79","span":{"begin":33,"end":38},"obj":"Body_part"},{"id":"T80","span":{"begin":309,"end":315},"obj":"Body_part"},{"id":"T81","span":{"begin":611,"end":616},"obj":"Body_part"}],"attributes":[{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T61","span":{"begin":33,"end":38},"obj":"Body_part"},{"id":"T62","span":{"begin":611,"end":616},"obj":"Body_part"}],"attributes":[{"id":"A61","pred":"uberon_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A62","pred":"uberon_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T174","span":{"begin":58,"end":66},"obj":"Disease"},{"id":"T175","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"T176","span":{"begin":390,"end":398},"obj":"Disease"},{"id":"T177","span":{"begin":679,"end":687},"obj":"Disease"}],"attributes":[{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A176","pred":"mondo_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T289","span":{"begin":33,"end":38},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T290","span":{"begin":33,"end":38},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T291","span":{"begin":185,"end":188},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T292","span":{"begin":309,"end":315},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T293","span":{"begin":351,"end":354},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T294","span":{"begin":463,"end":475},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T295","span":{"begin":492,"end":493},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T296","span":{"begin":572,"end":575},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T297","span":{"begin":587,"end":588},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T298","span":{"begin":611,"end":616},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T299","span":{"begin":611,"end":616},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T57","span":{"begin":260,"end":278},"obj":"Chemical"},{"id":"T58","span":{"begin":280,"end":290},"obj":"Chemical"},{"id":"T59","span":{"begin":339,"end":350},"obj":"Chemical"},{"id":"T60","span":{"begin":745,"end":747},"obj":"Chemical"}],"attributes":[{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T229","span":{"begin":0,"end":78},"obj":"Sentence"},{"id":"T230","span":{"begin":79,"end":176},"obj":"Sentence"},{"id":"T231","span":{"begin":177,"end":399},"obj":"Sentence"},{"id":"T232","span":{"begin":400,"end":733},"obj":"Sentence"},{"id":"T233","span":{"begin":734,"end":874},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"924","span":{"begin":16,"end":32},"obj":"Gene"},{"id":"925","span":{"begin":58,"end":66},"obj":"Disease"},{"id":"934","span":{"begin":745,"end":747},"obj":"Gene"},{"id":"935","span":{"begin":244,"end":256},"obj":"Chemical"},{"id":"936","span":{"begin":260,"end":278},"obj":"Chemical"},{"id":"937","span":{"begin":280,"end":290},"obj":"Chemical"},{"id":"938","span":{"begin":339,"end":350},"obj":"Chemical"},{"id":"939","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"940","span":{"begin":390,"end":398},"obj":"Disease"},{"id":"941","span":{"begin":679,"end":687},"obj":"Disease"}],"attributes":[{"id":"A924","pred":"tao:has_database_id","subj":"924","obj":"Gene:2770"},{"id":"A925","pred":"tao:has_database_id","subj":"925","obj":"MESH:C000657245"},{"id":"A934","pred":"tao:has_database_id","subj":"934","obj":"Gene:2770"},{"id":"A936","pred":"tao:has_database_id","subj":"936","obj":"MESH:D006886"},{"id":"A937","pred":"tao:has_database_id","subj":"937","obj":"MESH:C000606551"},{"id":"A938","pred":"tao:has_database_id","subj":"938","obj":"MESH:C462182"},{"id":"A939","pred":"tao:has_database_id","subj":"939","obj":"MESH:C000657245"},{"id":"A940","pred":"tao:has_database_id","subj":"940","obj":"MESH:C000657245"},{"id":"A941","pred":"tao:has_database_id","subj":"941","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?\n`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources)."}